BIOMAT Database Logo BIOMAT Database Logo

Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. 1991

T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Second Department of Medicine, Okayama University Medical School, Japan.

Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.
January 1990, Cancer chemotherapy and pharmacology,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer.
January 1993, Cancer chemotherapy and pharmacology,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
[Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer].
May 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
November 1999, British journal of cancer,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report.
December 1992, Seminars in oncology,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
December 2000, Lung cancer (Amsterdam, Netherlands),
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.
February 1992, American journal of clinical oncology,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Phase II trial of cytarabine, cisplatin and vindesine for advanced non-small cell lung cancer.
February 1990, Tumori,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study.
August 2003, American journal of clinical oncology,
T Ohnoshi, and S Hiraki, and N Ueda, and M Fujii, and K Machida, and H Ueoka, and S Kawahara, and A Kozuka, and K Kiura, and T Moritaka
Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
August 1993, American journal of clinical oncology,
Copied contents to your clipboard!